Current Status
Not Enrolled
Get Started

Takeaways from the course:

  • Heart failure is becoming more prevalent and carries a poor prognosis, independent of ejection fraction.
  • There are no proven treatments to improve outcomes in HFpEF – spironolactone and sacubitril/valsartan may be options for refractory patients
  • For HFrEF patients who remain symptomatic despite evidence-based therapies (including ACEi/ARB, BB, MRA)